Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499063 | 1.00 | NR1H2 (0.46) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL22346776 | 1.00 | NR1H2 (0.46) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL13567959 | 0.92 | NR1H2 (0.43) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL13568017 | 0.92 | NR1H2 (0.43) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL23867140 | 0.90 | NR1H2 (0.43) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL28950964 | 0.90 | NR1H2 (0.43) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL28722436 | 0.88 | SETD7 (0.42) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL28722434 | 0.88 | SETD7 (0.42) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL15217058 | 0.88 | SETD7 (0.42) | NR1H2SETD7MEN1ALDH1A1MAPT | |
| SCHEMBL3964253 | 0.87 | SMARCA2 (0.42) | NR1H2SETD7MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4185328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | Genentech, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | NR1H2 2015/4885SETD7 3512/4885MEN1 4258/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | NR1H2 909/4885SETD7 1744/4885MEN1 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.